New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
18:41 EDTZNGA, TKMR, SCTY, ANET, FOLD, POST, LULU, NVDA, UBNT, MELI, SLXP, CPST, MNST, MDVN, LRADOn The Fly: After Hours Movers
UP AFTER EARNINGS: MercadoLibre (MELI), up 14.2%... Amicus Therapeutics (FOLD), up 10.5%... LRAD Corporation (LRAD), up 18%... Ubiquiti Networks (UBNT), up 7%... Arista Networks (ANET), up 8.8%... Medivation (MDVN), up 4.2%... NVIDIA (NVDA), up 4.5%... SolarCity (SCTY), up 4.6%... Monster Beverage (MNST), up 2.5%. ALSO HIGHER: Lululemon Athletica (LULU), up 5.7% following announcement that founder Chip Wilson will sell half his stake to Advent International... Tekmira Pharmaceuticals (TKMR), up 7.2% after announcing that the FDA verbally confirmed they have modified the full clinical hold placed on the TKM-Ebola to a partial clinical hold. DOWN AFTER EARNINGS: Capstone Turbine (CPST), down 12%... Post Holdings (POST), down 13.1% after reporting quarterly results and that it acquired American Blanching for $128M in cash... Zynga (ZNGA), down 7.2% after lowering fiscal 2014 guidance... Salix Pharmaceuticals (SLXP), down 3.4%.
News For MELI;FOLD;LRAD;UBNT;ANET;MDVN;NVDA;SCTY;MNST;LULU;TKMR;CPST;POST;ZNGA;SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 22, 2015
06:02 EDTLULUStocks with implied volatility below IV index mean; QIHU LULU
Subscribe for More Information
June 19, 2015
16:26 EDTCPSTCapstone Turbine receives Nasdaq approval to transfer listing
On June 18, Capstone Turbine received approval from the Nasdaq Stock Market to transfer the listing of the company’s common stock from the Nasdaq Global Market to the Nasdaq Capital Market. This transfer will be effective at the opening of business on Monday, June 22. The company’s common stock will continue to trade under the symbol “CPST.” The Nasdaq Capital Market is a continuous trading market that operates in substantially the same manner as the Nasdaq Global Market and requires listed companies to meet certain financial requirements and comply with Nasdaq’s corporate governance requirements.
14:33 EDTTKMRTekmira main driver still hepatitis B program, says Leerink
Subscribe for More Information
09:18 EDTTKMROn The Fly: Pre-market Movers
Subscribe for More Information
08:01 EDTTKMRTekmira provides update on TKM-Ebola-Guinea
Tekmira Pharmaceuticals announced that the Phase II clinical trial of TKM-Ebola-Guinea has reached a predefined statistical endpoint and enrollment has been closed. The endpoint indicated that continuing enrollment was not likely to demonstrate an overall therapeutic benefit. Data analysis is ongoing and the full results will be made available as soon as possible. In this trial, TKM-Ebola-Guinea is being evaluated for efficacy in Ebola virus infected patients in Sierra Leone, West Africa. The Phase II single arm trial called RAPIDE, or Rapid Assessment of Potential Interventions & Drugs for Ebola, is open-label with a concurrent observational study of Ebola virus disease in Sierra Leone.
June 18, 2015
17:02 EDTPOSTPost Holdings provides additional avian influenza update
Post Holdings provided an update with respect to the recent avian influenza outbreak affecting Post's Michael Foods egg business. As reported on May 27, a company-owned flock in Nebraska tested positive for AI. Several rounds of subsequent testing did not confirm the presumptive positive, and the flock was today released from quarantine by the USDA. As a result, the company's total affected egg supply is now approximately 25% of its annualized egg volume commitments. As a result of aggressive cost management, discontinuation of certain product lines and pricing actions, Post management continues to expect the negative impact of AI for fiscal 2015 on Adjusted EBITDA to be in line with previous guidance of approximately $20M.
June 17, 2015
13:17 EDTNVDAAMD advances after introducing next-generation Radeon graphics line-up
Shares of AMD (AMD) are rising today after the company introduced its next-generation Radeon graphics line-up yesterday at the Electronic Entertainment Expo or E3. "The AMD next-generation graphics cards mark a technology turning point in PC gaming, bringing super high resolutions, exceptional VR experiences, smoother gameplay, support for new, advanced APIs like DirectX 12 and Vulkan, and groundbreaking form factors to gamers everywhere through a top-to-bottom line of GPUs that fit virtually every need and budget", the company noted. Radeon R9 300 series GPUs and Radeon R7 series GPUs are scheduled for select retailer availability on June 18. The AMD Radeon R9 Fury X GPU is planned to be available on June 24. AMD competes with NVIDIA (NVDA) in the graphics processor unit or GPU product space. Shares of AMD are up around 5% to $2.47 while NVIDIA shares are up 0.75% to $21.49 in afternoon trading.
11:50 EDTSCTYSolarCity management to meet with Needham
Subscribe for More Information
10:00 EDTANETOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AbbVie (ABBV) initiated with an Overweight at Piper Jaffray... Arista Networks (ANET) initiated with a Buy at Sterne Agee CRT... Astec (ASTE) initiated with a Buy at Maxim... Bristol-Myers (BMY) initiated with an Underweight at Piper Jaffray... Community Healthcare (CHCT) initiated with an Outperform at Oppenheimer... Eli Lilly (LLY) initiated with an Overweight at Piper Jaffray... Fitbit (FIT) initiated with a Buy ahead of IPO at Dougherty... Hortonworks (HDP) initiated with a Buy at Mizuho... II-VI (IIVI) initiated with a Buy at Benchmark Co.... J Sainsbury (JSAIY) initiated with an Underperform at Credit Suisse... McDermott (MDR) initiated with an Outperform at Cowen... Merck (MRK) initiated with a Neutral at Piper Jaffray... Molina Healthcare (MOH) initiated with a Buy at UBS... Pacific DataVision (PDVW) initiated with a Buy at Canaccord... Pfizer (PFE) initiated with an Overweight at Piper Jaffray... Quest Resource (QRHC) initiated with a Buy at Roth Capital... Regional Management (RM) initiated with a Buy at Janney Capital... Rofin-Sinar (RSTI) initiated with a Buy at Benchmark Co.... Salesforce (CRM) initiated with a Neutral at Exane BNP Paribas... Sprouts Farmers Markets (SFM) initiated with a Neutral at Cleveland Research... Tesco (TSCDY) initiated with an Underperform at Credit Suisse... WM Morrison (MRWSY) initiated with a Neutral at Credit Suisse... WWE (WWE) initiated with a Buy at BTIG... World Acceptance (WRLD) initiated with a Buy at Janney Capital... Zafgen (ZFGN) initiated with a Buy at SunTrust.
10:00 EDTNVDAOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:46 EDTZNGAJefferies to hold company meetings at E3 Expo
Subscribe for More Information
09:04 EDTNVDANVIDIA upgraded to Buy from Neutral at Tigress Financial
Subscribe for More Information
07:08 EDTMDVNMedivation, Astellas Pharma announce enrollment of first patients in TRUMPET
Subscribe for More Information
07:07 EDTMDVNMedivation and Astellas Pharma enroll first patients in prostate cancer registry
Astellas (ALPMY) and Medivation (MDVN) have enrolled the first patients in TRUMPET - Treatment Registry for Outcomes in CRPC Patients -, a prospective observational patient registry designed to better understand the unique needs and treatment patterns for patients with castration-resistant prostate cancer. The registry will enroll and evaluate 2,000 patients diagnosed with CRPC from urology and oncology sites across the U.S. TRUMPET is currently enrolling eligible patients and their caregivers; the study will be completed in 2020.
06:38 EDTANETArista Networks initiated with a Buy at Sterne Agee CRT
Subscribe for More Information
June 16, 2015
11:11 EDTMNSTMonster Beverage climbs after added to Citi Focus List
Energy drink maker Monster Beverage (MNST) is advancing after Citi added the stock to its Focus List, saying that the company has many potential positive catalysts. WHAT'S NEW: Monster's stock can rise significantly from current levels, as it has many potential positive catalysts that can kick in over the next 12 months, Citi analyst Wendy Nicholson wrote in a note to investors today. Specifically, the company can enter new markets such as China and its overseas profit margins may increase, the analyst stated, adding that Monster may also sign new distribution deals in foreign markets and launch new products. Other potential catalysts include signs that the distribution of the company's drinks in the U.S. has become smoother in the wake of its transition to Coca-Cola's (KO) system and the possibility that the soda giant will increase its stake in Monster, the analyst believes. Monster could initiate large share repurchases, given the huge amount of cash it received from Coca-Cola, the analyst stated. She predicted that the company's earnings before interest and taxes would grow at an "outsized" compound annual growth rate of 12% over the next five years and kept a $155 price target and Buy rating on the stock. WHAT'S NOTABLE: UBS on June 12 upgraded Monster to Buy from Neutral, saying that the short-term risks facing the company were already priced into the stock, while the beverage maker's U.S. and foreign growth outlook is strong. The analyst predicted that Coca-Cola would increase its stake in the company to 25% from its current 16.7% level. Also on June 12, Monster and Coca-Cola announced that the acquisition of the 16.7% stake in Monster by Coke had been closed. PRICE ACTION: In late morning trading, Monster climbed 4% to $132.
09:47 EDTZNGACapital World reports 10.2% passive stake in Zynga
Subscribe for More Information
09:09 EDTCPSTOn The Fly: Pre-market Movers
Subscribe for More Information
08:59 EDTANETArista Networks price target raised to $92 on solid execution at BofA/Merrill
Subscribe for More Information
07:25 EDTMNSTMonster Beverage added to U.S. Focus List at Citi
Citi added Monster Beverage to its U.S. Focus List saying it sees "considerable" upside potential from current share levels. Citi calls Monster its top pick in U.S. Beverages and keeps a Buy rating on the stock with a $155 price target.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use